Brief: Pherecydes Pharma Granted Patent For Its Anti-Pseudomonas Aeruginosa Phages In China
08/03/2022 16:56
March 8 (Reuters) - Pherecydes Pharma SA ALPHE.PA :
* PHERECYDES PHARMA EXTENDS ITS INTELLECTUAL PROPERTY IN
CHINA
WITH A FIRST PATENT GRANTED FOR ITS ANTI-PSEUDOMONAS AERUGINOSA
PHAGES IN THIS TERRITORY
* SECOND PATENT IN CHINA, FOLLOWING ONE GRANTED IN DECEMBER
FOR
ITS ANTI-STAPHYLOCOCCUS AUREUS PHAGES, GIVES COMPANY PROTECTION
UNTIL END OF 2034 ON THIS LARGE MARKET
Source text for Eikon: ID:nBw5Dn8v6a
Further company coverage: ALPHE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes